Literature DB >> 17446880

A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood.

Dan G Duda1, Kenneth S Cohen, David T Scadden, Rakesh K Jain.   

Abstract

Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor cells (CPCs) represent two cell populations that are thought to play important roles in tissue vascularization. CECs and CPCs are currently studied as surrogate markers in patients for more than a dozen pathologies, including heart disease and cancer. However, data interpretation has often been difficult because of multiple definitions, methods and protocols used to evaluate and count these cells by different laboratories. Here, we propose a cytometry protocol for phenotypic identification and enumeration of CECs and CPCs in human blood using four surface markers: CD31, CD34, CD133 and CD45. This method allows further phenotypic analyses to explore the biology of these cells. In addition, it offers a platform for longitudinal studies of these cells in patients with different pathologies. The protocol is relatively simple, inexpensive and can be adapted for multiple flow cytometer types or software. The procedure should take 2-2.5 h, and is expected to detect 0.1-6.0% viable CECs and 0.01-0.20% CPCs within blood mononuclear cell population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17446880      PMCID: PMC2686125          DOI: 10.1038/nprot.2007.111

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  11 in total

1.  Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma.

Authors:  S Monestiroli; P Mancuso; A Burlini; G Pruneri; C Dell'Agnola; A Gobbi; G Martinelli; F Bertolini
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

2.  Resting and activated endothelial cells are increased in the peripheral blood of cancer patients.

Authors:  P Mancuso; A Burlini; G Pruneri; A Goldhirsch; G Martinelli; F Bertolini
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 3.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

Authors:  Shahin Rafii; David Lyden; Robert Benezra; Koichi Hattori; Beate Heissig
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

4.  Detection of circulating endothelial cells: CD146-based magnetic separation enrichment or flow cytometric assay?

Authors:  Françoise Dignat-George; Florence Sabatier; Andrew Blann; Alexander Woywodt
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

5.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

Review 6.  The multifaceted circulating endothelial cell in cancer: towards marker and target identification.

Authors:  Francesco Bertolini; Yuval Shaked; Patrizia Mancuso; Robert S Kerbel
Journal:  Nat Rev Cancer       Date:  2006-10-05       Impact factor: 60.716

Review 7.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

8.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells.

Authors:  Alexandra Aicher; Christopher Heeschen; Christiane Mildner-Rihm; Carmen Urbich; Christian Ihling; Katja Technau-Ihling; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Nat Med       Date:  2003-10-12       Impact factor: 53.440

9.  Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy.

Authors:  Dan G Duda; Kenneth S Cohen; Emmanuelle di Tomaso; Patrick Au; Rachael J Klein; David T Scadden; Christopher G Willett; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2006-03-20       Impact factor: 44.544

10.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

View more
  114 in total

1.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Circulation of progenitor cells in obese and lean colorectal cancer patients.

Authors:  Charles F Bellows; Yan Zhang; Jinyun Chen; Marsha L Frazier; Mikhail G Kolonin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-19       Impact factor: 4.254

3.  Identification of a restriction point at the M/G1 transition in CHO cells.

Authors:  E Hullemann; J J M Bijvelt; A J Verkleij; C T Verrips; J Boonstra
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

Review 4.  Endothelial progenitor cells: current issues on characterization and challenging clinical applications.

Authors:  Thomas Resch; Andreas Pircher; Christian M Kähler; Johann Pratschke; Wolfgang Hilbe
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

5.  Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer.

Authors:  Yuichi Sakamori; Katsuhiro Masago; Katsuyuki Ohmori; Yosuke Togashi; Hiroki Nagai; Chiyuki Okuda; Young Hak Kim; Satoshi Ichiyama; Michiaki Mishima
Journal:  Cancer Sci       Date:  2012-04-15       Impact factor: 6.716

Review 6.  Regeneration of the vascular compartment.

Authors:  M U Becher; G Nickenig; N Werner
Journal:  Herz       Date:  2010-08       Impact factor: 1.443

7.  Recombinant human interleukin-11 treatment enhances collateral vessel growth after femoral artery ligation.

Authors:  Julius Aitsebaomo; Siddharth Srivastava; Hua Zhang; Sushmita Jha; Zhongjing Wang; Stephan Winnik; Anka N Veleva; Xinchun Pi; Pamela Lockyer; James E Faber; Cam Patterson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

8.  Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.

Authors:  Neil S Horowitz; Richard T Penson; Dan G Duda; Emmanuelle di Tomaso; Yves Boucher; Marek Ancukiewicz; Kenneth S Cohen; Suzanne Berlin; Carolyn N Krasner; Marsha A Moses; Rakesh K Jain
Journal:  Clin Ovarian Cancer Other Gynecol Malig       Date:  2011-06

9.  Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells.

Authors:  Julie A Mund; Myka L Estes; Mervin C Yoder; David A Ingram; Jamie Case
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-01-26       Impact factor: 8.311

Review 10.  Following up tumour angiogenesis: from the basic laboratory to the clinic.

Authors:  José L Orgaz; Beatriz Martínez-Poveda; Nuria I Fernández-García; Benilde Jiménez
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.